Tenaya Therapeutics, Inc. (TNYA) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.05
↓-26% vs avg
5yr avg: 1.42
30Y Low0.4·High2.8
ROE
↓
-83.8%
↑-28% vs avg
5yr avg: -65.3%
30Y Low-96%·High-35%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TNYA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tenaya Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $184M | $109M | $121M | $239M | $90M | $782M | — | — |
| Enterprise Value | $94M | $19M | $131M | $206M | $10M | $760M | — | — |
| P/E Ratio → | -1.44 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.05 | 0.88 | 1.31 | 1.71 | 0.37 | 2.81 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TNYA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
TNYA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -83.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -83.8% | -83.8% | -95.7% | -64.8% | -47.4% | -34.8% | -80.2% | — |
| ROA | -67.9% | -67.9% | -76.5% | -55.2% | -41.5% | -31.3% | -41.2% | -67.8% |
| ROIC | -103.2% | -103.2% | -83.5% | -73.1% | -44.9% | -40.9% | — | — |
| ROCE | -79.3% | -79.3% | -92.1% | -65.2% | -45.7% | -33.2% | -44.0% | -81.8% |
TNYA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $101M exceeds total debt of $11M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.15 | 0.09 | 0.06 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.73 | 0.10 | -0.24 | -0.33 | -0.08 | -0.92 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($101M) exceeds total debt ($11M)
TNYA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Tenaya Therapeutics, Inc.'s current ratio of 6.84x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.91x to 6.84x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.84 | 6.84 | 4.22 | 4.91 | 7.99 | 11.73 | 25.78 | 6.73 |
| Quick Ratio | 6.84 | 6.84 | 4.22 | 4.91 | 7.99 | 11.73 | 25.78 | 6.73 |
| Cash Ratio | 6.51 | 6.51 | 3.85 | 4.60 | 7.69 | 11.54 | 25.50 | 6.46 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
TNYA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tenaya Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $153M | $85M | $74M | $45M | $41M | $41M | $27M |
Peer Comparison
Compare TNYA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TNYAYou | $184M | -1.4 | — | — | — | — | -83.8% | -103.2% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See TNYA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNYA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNYA vs RCKT
Side-by-side business, growth, and profitability comparison vs Rocket Pharmaceuticals, Inc..
Start ComparisonTNYA — Frequently Asked Questions
Quick answers to the most common questions about buying TNYA stock.
What is Tenaya Therapeutics, Inc.'s P/E ratio?
Tenaya Therapeutics, Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
What is Tenaya Therapeutics, Inc.'s ROE?
Tenaya Therapeutics, Inc.'s return on equity (ROE) is -83.8%. The historical average is -67.8%.
Is TNYA stock overvalued?
Based on historical data, Tenaya Therapeutics, Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.